Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 16/20 | 0.55 |
| ▸ | CTSS | P25774 | 13/20 | 0.55 |
| ▸ | CTSB | P07858 | 12/20 | 0.55 |
| ▸ | CTSC | P53634 | 2/20 | 0.48 |
| ▸ | CTSL | P07711 | 3/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL347231 | 1.00 | CTSK (0.55) | CTSKCTSSCTSBCTSCCTSL | |
| SCHEMBL5407806 | 0.91 | CTSK (0.50) | CTSKCTSSCTSBCTSCCTSL | |
| Hydrochloric Acid SCHEMBL28421511 | 0.90 | CTSK (0.49) | CTSKCTSSCTSBCTSCCTSL | |
| Hydrochloric Acid SCHEMBL28421509 | 0.90 | CTSK (0.49) | CTSKCTSSCTSBCTSCCTSL | |
| SCHEMBL11889813 | 0.90 | CTSS (0.62) | CTSKCTSSCTSBCTSCCTSL | |
| SCHEMBL8296697 | 0.88 | CTSC (0.50) | CTSKCTSSCTSBCTSCCTSL | |
| SCHEMBL11889693 | 0.86 | CTSK (0.47) | CTSKCTSSCTSBCTSCCTSL | |
| SCHEMBL3881249 | 0.83 | CTSK (0.58) | CTSKCTSSCTSBCTSCCTSL | |
| SCHEMBL18910071 | 0.80 | CTSC (0.53) | CTSKCTSSCTSBCTSCCTSL | |
| SCHEMBL347349 | 0.79 | CTSS (0.67) | CTSKCTSSCTSBCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2032535-B1 | SPIROCYCLIC NITRILES AS PROTEASE INHIBITORS | SANOFI SA (FR) | 2012-08-01 | — | — | EP | claimed |
| EP-2520568-B1 | Spirocyclic nitriles as inhibitors of protease | SANOFI SA (FR) | 2015-09-09 | — | — | EP | disclosed |
| US-20140073662-A1 | Spirocyclic nitriles as protease inhibitors | SANOFI (FR) | 2014-03-13 | — | — | US | disclosed |
| US-8609681-B2 | Spirocyclic nitriles as protease inhibitors | SANOFI (FR) | 2013-12-17 | — | — | US | disclosed |
| EP-2520568-A1 | Spirocyclic nitriles as inhibitors of protease | SANOFI (FR) | 2012-11-07 | — | — | EP | disclosed |
| EP-2032535-B1 | SPIROCYCLIC NITRILES AS PROTEASE INHIBITORS | SANOFI SA (FR) | 2012-08-01 | — | — | EP | disclosed |
| US-20120015933-A1 | Spirocyclic nitriles as protease inhibitors | SANOFI-AVENTIS (FR) | 2012-01-19 | — | — | US | disclosed |
| US-8039480-B2 | Spirocyclic nitriles as protease inhibitors | SANOFI-AVENTIS (FR) | 2011-10-18 | — | — | US | disclosed |
| US-20090275523-A1 | Spirocyclic nitriles as protease inhibitors | SANOFI-AVENTIS (FR) | 2009-11-05 | — | — | US | disclosed |
| EP-2032535-A1 | SPIROCYCLIC NITRILES AS PROTEASE INHIBITORS | Sanofi-Aventis (FR) | 2009-03-11 | — | — | EP | disclosed |
| WO-2007137738-A1 | SPIROCYCLIC NITRILES AS PROTEASE INHIBITORS | SANOFI-AVENTIS (DE) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275523-A1 | Spirocyclic nitriles as protease inhibitors | CTRL, SERPINB1, PREP | CTSK 87/4885CTSS 24/4885CTSB 31/4885 |
| US-20120015933-A1 | Spirocyclic nitriles as protease inhibitors | CTRL, SERPINB1, PREP | CTSK 87/4885CTSS 24/4885CTSB 31/4885 |
| US-20140073662-A1 | Spirocyclic nitriles as protease inhibitors | CTRL, SERPINB1, PREP | CTSK 87/4885CTSS 24/4885CTSB 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.